Johnson & Johnson announced today that worldwide consumer product sales jumped 13.1% to $4.1 billion for the third quarter. Growth from  operations accounted for 9.4% of the gain and a positive impact from currency added 3.7%. Domestic sales increased 11.2%, while international sales increased 14.7%; 8.1% from operations and 6.6% from currency. Sales results reflect the strong performance of the U.S. launch of Zyrtec, an over-the-counter allergy treatment; Listerine antiseptic mouthrinse; ...